Efficient Screening of Cytochrome P450 BM3 Mutants for Their Metabolic Activity and Diversity toward a Wide Set of Drug-Like Molecules in Chemical Space

In the present study, the diversity of a library of drug-metabolizing bacterial cytochrome P450 (P450) BM3 mutants was evaluated by a liquid chromatography-mass spectrometry (LC-MS)-based screening method. A strategy was designed to identify a minimal set of BM3 mutants that displays differences in regio- and stereoselectivities and is suitable to metabolize a large fraction of drug chemistry space. We first screened the activities of six structurally diverse BM3 mutants toward a library of 43 marketed drugs (encompassing a wide range of human P450 phenotypes, cLogP values, charges, and molecular weights) using a rapid LC-MS method with an automated method development and data-processing system. Significant differences in metabolic activity were found for the mutants tested and based on this drug library screen; nine structurally diverse probe drugs were selected that were subsequently used to study the metabolism of a library of 14 BM3 mutants in more detail. Using this alternative screening strategy, we were able to select a minimal set of BM3 mutants with high metabolic activities and diversity with respect to substrate specificity and regiospecificity that could produce both human relevant and BM3 unique drug metabolites. This panel of four mutants (M02, MT35, MT38, and MT43) was capable of producing P450-mediated metabolites for 41 of the 43 drugs tested while metabolizing 77% of the drugs by more than 20%. We observed this as the first step in our approach to use of bacterial P450 enzymes as general reagents for lead diversification in the drug development process and the biosynthesis of drug(-like) metabolites.

[1]  M. Schwab,et al.  Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation , 2008, Analytical and bioanalytical chemistry.

[2]  R Scott Obach,et al.  Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. , 2009, Chemical research in toxicology.

[3]  N. Vermeulen,et al.  Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants. , 2005, Analytical biochemistry.

[4]  N. Vermeulen,et al.  Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. , 2007, Journal of medicinal chemistry.

[5]  Matthias Dietrich,et al.  Altering the regioselectivity of the subterminal fatty acid hydroxylase P450 BM-3 towards gamma- and delta-positions. , 2009, Journal of biotechnology.

[6]  N. Vermeulen,et al.  Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. , 2008, Chemico-biological interactions.

[7]  N. Vermeulen,et al.  Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome p450s. , 2008, Chemical research in toxicology.

[8]  Sabine Laschat,et al.  Rational Design of a Minimal and Highly Enriched CYP102A1 Mutant Library with Improved Regio‐, Stereo‐ and Chemoselectivity , 2009, Chembiochem : a European journal of chemical biology.

[9]  L. Narhi,et al.  Characterization of a catalytically self-sufficient 119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in Bacillus megaterium. , 1986, The Journal of biological chemistry.

[10]  U. Schwaneberg,et al.  A P450 BM-3 mutant hydroxylates alkanes, cycloalkanes, arenes and heteroarenes. , 2001, Journal of biotechnology.

[11]  D. Manallack,et al.  Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies , 2007 .

[12]  K. R. Marshall,et al.  P450 BM3: the very model of a modern flavocytochrome. , 2002, Trends in biochemical sciences.

[13]  R. Schmid,et al.  Engineering Cytochrome P450 BM-3 for Oxidation of Polycyclic Aromatic Hydrocarbons , 2001, Applied and Environmental Microbiology.

[14]  N. Vermeulen,et al.  Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3 , 2008, Proteins.

[15]  T. Poulos,et al.  The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid , 1997, Nature Structural Biology.

[16]  Matthias Kittelmann,et al.  Recombinant human cytochrome P450 monooxygenases for drug metabolite synthesis. , 2010, Biotechnology and bioengineering.

[17]  J. Halpert,et al.  Directed evolution of mammalian cytochromes P450 for investigating the molecular basis of enzyme function and generating novel biocatalysts , 2005, Biochemical and biophysical research communications.

[18]  K. Auclair,et al.  Progress towards the easier use of P450 enzymes. , 2006, Molecular bioSystems.

[19]  Frances H Arnold,et al.  Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3. , 2003, Journal of the American Chemical Society.

[20]  F. Arnold,et al.  Enantioselective alpha-hydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450 BM-3. , 2006, Journal of the American Chemical Society.

[21]  F. Arnold,et al.  Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. , 2006, Biotechnology and bioengineering.

[22]  N. Vermeulen,et al.  Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3. , 2006, Biochemical and biophysical research communications.

[23]  R. Bernhardt,et al.  Cytochromes P450 as versatile biocatalysts. , 2006, Journal of biotechnology.

[24]  F. Arnold,et al.  Stereoselective Hydroxylation of an Achiral Cyclopentanecarboxylic Acid Derivative Using Engineered P450s BM‐3. , 2005 .

[25]  R D Schmid,et al.  Directed evolution of the fatty-acid hydroxylase P450 BM-3 into an indole-hydroxylating catalyst. , 2000, Chemistry.

[26]  L. Wong,et al.  Protein engineering of Bacillus megaterium CYP102. The oxidation of polycyclic aromatic hydrocarbons. , 2001, European journal of biochemistry.

[27]  Frances H Arnold,et al.  Enantioselective epoxidation of terminal alkenes to (R)- and (S)-epoxides by engineered cytochromes P450 BM-3. , 2006, Chemistry.

[28]  R D Schmid,et al.  Rational evolution of a medium chain-specific cytochrome P-450 BM-3 variant. , 2001, Biochimica et biophysica acta.

[29]  F. Arnold,et al.  Stereoselective hydroxylation of an achiral cyclopentanecarboxylic acid derivative using engineered P450s BM-3. , 2005, Chemical communications.

[30]  Heung-Chae Jung,et al.  Generation of the Human Metabolite Piceatannol from the Anticancer-Preventive Agent Resveratrol by Bacterial Cytochrome P450 BM3 , 2009, Drug Metabolism and Disposition.

[31]  Frances H Arnold,et al.  Chemo-enzymatic fluorination of unactivated organic compounds. , 2009, Nature chemical biology.

[32]  R. J. Kenny,et al.  Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options. , 2008, Chemical communications.

[33]  Heung-Chae Jung,et al.  Generation of Human Chiral Metabolites of Simvastatin and Lovastatin by Bacterial CYP102A1 Mutants , 2011, Drug Metabolism and Disposition.

[34]  F. Guengerich,et al.  New applications of bacterial systems to problems in toxicology. , 1996, Critical reviews in toxicology.

[35]  Frances H Arnold,et al.  Engineered alkane-hydroxylating cytochrome P450(BM3) exhibiting nativelike catalytic properties. , 2007, Angewandte Chemie.

[36]  Kwang-Hyeon Liu,et al.  Generation of Human Metabolites of 7-Ethoxycoumarin by Bacterial Cytochrome P450 BM3 , 2008, Drug Metabolism and Disposition.

[37]  C. Hobbs,et al.  New cloning vectors and techniques for easy and rapid restriction mapping. , 1988, Gene.

[38]  F. Arnold,et al.  A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds. , 2009, Chemistry.